Coblopasvir

Coblopasvir
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name Methyl N-[(2S)-1-[(2S)-2-[5-[4-[7-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,3-benzodioxol-4-yl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate;
CAS Number	1312608-46-0;
PubChem CID	58316387;
DrugBank	DB15315;
UNII	67XWL3R65W;
Chemical and physical data
Formula	C41H50N8O8
Molar mass	782.899 g·mol−1

Coblopasvir is a pharmaceutical drug for the treatment of hepatitis C.^[1]

In China, it is approved for use in combination with sofosbuvir for treating naïve or interferon‐experienced adults chronically monoinfected patients with HCV of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.^[2]

References

^ . doi:10.1111/jvh.13208. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)
^ . doi:10.1111/liv.14633. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[1] . doi:10.1111/jvh.13208. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)

[2] . doi:10.1111/liv.14633. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)

[1]